(Q59120277)
Statements
Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response (English)
Karen I Kroeker
Levinus A Dieleman
Brendan P Halloran
Richard N Fedorak
1 September 2015